Ovarian cancer: The fallopian tube as the site of origin and opportunities for prevention

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

High-grade serous carcinoma (HGSC) is the most common and aggressive histotype of epithelial ovarian cancer (EOC), and it is the predominant histotype associated with hereditary breast and ovarian cancer syndrome (HBOC). Mutations in BRCA1 and BRCA2 are responsible for most of the known causes of HBOC, while mutations in mismatch repair genes and several genes of moderate penetrance are responsible for the remaining known hereditary risk. Women with a history of familial ovarian cancer or with known germline mutations in highly penetrant genes are offered the option of risk-reducing surgery that involves the removal of the ovaries and fallopian tubes (salpingo-oophorectomy). Growing evidence now supports the fallopian tube epithelia as an etiological site for the development of HGSC and consequently, salpingectomy alone is emerging as a prophylactic option. This review discusses the site of origin of EOC, the rationale for risk-reducing salpingectomy in the high-risk population, and opportunities for salpingectomy in the low-risk population.

Original languageEnglish (US)
Article number108
JournalFrontiers in Oncology
Volume6
Issue numberMAY
DOIs
StatePublished - 2016

Fingerprint

Fallopian Tube Neoplasms
Ovarian Neoplasms
Salpingectomy
Hereditary Breast and Ovarian Cancer Syndrome
Fallopian Tubes
Genes
Carcinoma
Mutation
DNA Mismatch Repair
Penetrance
Germ-Line Mutation
Ovariectomy
Population
Ovary
Epithelium

Keywords

  • BRCA1
  • BRCA2
  • Fallopian tubes
  • Ovarian cancers
  • Salpingectomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ovarian cancer : The fallopian tube as the site of origin and opportunities for prevention. / George, Sophia; Garcia, Ruslan; Slomovitz, Brian.

In: Frontiers in Oncology, Vol. 6, No. MAY, 108, 2016.

Research output: Contribution to journalReview article

@article{8b4f13b7547d49ae989177666bf83b7e,
title = "Ovarian cancer: The fallopian tube as the site of origin and opportunities for prevention",
abstract = "High-grade serous carcinoma (HGSC) is the most common and aggressive histotype of epithelial ovarian cancer (EOC), and it is the predominant histotype associated with hereditary breast and ovarian cancer syndrome (HBOC). Mutations in BRCA1 and BRCA2 are responsible for most of the known causes of HBOC, while mutations in mismatch repair genes and several genes of moderate penetrance are responsible for the remaining known hereditary risk. Women with a history of familial ovarian cancer or with known germline mutations in highly penetrant genes are offered the option of risk-reducing surgery that involves the removal of the ovaries and fallopian tubes (salpingo-oophorectomy). Growing evidence now supports the fallopian tube epithelia as an etiological site for the development of HGSC and consequently, salpingectomy alone is emerging as a prophylactic option. This review discusses the site of origin of EOC, the rationale for risk-reducing salpingectomy in the high-risk population, and opportunities for salpingectomy in the low-risk population.",
keywords = "BRCA1, BRCA2, Fallopian tubes, Ovarian cancers, Salpingectomy",
author = "Sophia George and Ruslan Garcia and Brian Slomovitz",
year = "2016",
doi = "10.3389/fonc.2016.00108",
language = "English (US)",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Ovarian cancer

T2 - The fallopian tube as the site of origin and opportunities for prevention

AU - George, Sophia

AU - Garcia, Ruslan

AU - Slomovitz, Brian

PY - 2016

Y1 - 2016

N2 - High-grade serous carcinoma (HGSC) is the most common and aggressive histotype of epithelial ovarian cancer (EOC), and it is the predominant histotype associated with hereditary breast and ovarian cancer syndrome (HBOC). Mutations in BRCA1 and BRCA2 are responsible for most of the known causes of HBOC, while mutations in mismatch repair genes and several genes of moderate penetrance are responsible for the remaining known hereditary risk. Women with a history of familial ovarian cancer or with known germline mutations in highly penetrant genes are offered the option of risk-reducing surgery that involves the removal of the ovaries and fallopian tubes (salpingo-oophorectomy). Growing evidence now supports the fallopian tube epithelia as an etiological site for the development of HGSC and consequently, salpingectomy alone is emerging as a prophylactic option. This review discusses the site of origin of EOC, the rationale for risk-reducing salpingectomy in the high-risk population, and opportunities for salpingectomy in the low-risk population.

AB - High-grade serous carcinoma (HGSC) is the most common and aggressive histotype of epithelial ovarian cancer (EOC), and it is the predominant histotype associated with hereditary breast and ovarian cancer syndrome (HBOC). Mutations in BRCA1 and BRCA2 are responsible for most of the known causes of HBOC, while mutations in mismatch repair genes and several genes of moderate penetrance are responsible for the remaining known hereditary risk. Women with a history of familial ovarian cancer or with known germline mutations in highly penetrant genes are offered the option of risk-reducing surgery that involves the removal of the ovaries and fallopian tubes (salpingo-oophorectomy). Growing evidence now supports the fallopian tube epithelia as an etiological site for the development of HGSC and consequently, salpingectomy alone is emerging as a prophylactic option. This review discusses the site of origin of EOC, the rationale for risk-reducing salpingectomy in the high-risk population, and opportunities for salpingectomy in the low-risk population.

KW - BRCA1

KW - BRCA2

KW - Fallopian tubes

KW - Ovarian cancers

KW - Salpingectomy

UR - http://www.scopus.com/inward/record.url?scp=84973530077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973530077&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00108

DO - 10.3389/fonc.2016.00108

M3 - Review article

AN - SCOPUS:84973530077

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAY

M1 - 108

ER -